Skip to main content
. 2020 May 6;20:388. doi: 10.1186/s12885-020-06901-6

Table 3.

Survival by miRNA expression for 39 dysregulated miRNAs (from Table 1)a,b,c,d

No. miRNA HR 95% CI P-value
1 hsa-miR-30e* 0.76 0.61–0.95 0.0179
2 hsa-miR-124 0.79 0.62–1.00 0.0459
3 hsa-miR-22 1.22 0.95–1.56 0.1166
4 hsa-miR-140-3p 0.84 0.67–1.05 0.1303
5 hsa-miR-143 0.85 0.68–1.06 0.1487
6 hsa-miR-150 0.85 0.67–1.08 0.1924
7 hsa-miR-106b 1.16 0.92–1.45 0.2022
8 hsa-miR-203 1.15 0.92–1.44 0.2197
9 hsa-miR-596 0.87 0.69–1.09 0.2285
10 hsa-miR-30a* 0.88 0.71–1.09 0.2389
11 hsa-miR-23b 0.88 0.70–1.10 0.2638
12 hsa-miR-183* 1.15 0.89–1.48 0.2763
13 hsa-miR-204 0.88 0.69–1.12 0.2852
14 hsa-miR-486-5p 0.89 0.69–1.13 0.3295
15 hsa-miR-196b 0.89 0.71–1.13 0.3435
16 hsa-miR-145 0.90 0.73–1.12 0.3544
17 hsa-miR-133b 0.90 0.72–1.12 0.3565
18 hsa-miR-133a 0.90 0.72–1.13 0.3815
19 hsa-miR-26b* 0.89 0.68–1.18 0.4180
20 hsa-miR-21* 1.09 0.87–1.37 0.4533
21 hsa-miR-885-5p 1.08 0.85–1.38 0.5286
22 hsa-miR-130b 1.08 0.84–1.39 0.5384
23 hsa-miR-639 1.09 0.83–1.43 0.5404
24 hsa-miR-21* 1.07 0.86–1.34 0.5411
25 hsa-miR-423-5p 1.07 0.84–1.37 0.5707
26 hsa-miR-95 0.94 0.74–1.19 0.5844
27 hsa-miR-708 0.95 0.75–1.20 0.6622
28 hsa-miR-378* 1.05 0.84–1.32 0.6677
29 hsa-let-7c 0.95 0.76–1.20 0.6779
30 hsa-miR-328 0.95 0.74–1.21 0.6869
31 hsa-miR-574–3p 0.95 0.75–1.21 0.6977
32 hsa-miR-139-5p 0.96 0.77–1.20 0.7210
33 hsa-miR-375 1.04 0.81–1.33 0.7731
34 hsa-miR-149 0.97 0.76–1.22 0.7813
35 hsa-miR-125b 0.97 0.77–1.23 0.8095
36 hsa-miR-99a* 1.01 0.81–1.26 0.9020
37 hsa-miR-422a 0.99 0.79–1.23 0.9074
38 hsa-miR-100 1.01 0.80–1.26 0.9548
39 hsa-miR-378 1.00 0.80–1.26 0.9770

amiRNA expression modeled as tumor/normal fold change using ordinal variable (0,1,2,3)

bmiRNAs shown in ascending order by P-value

cCox proportional hazards models adjusted for age, gender, metastasis, stage

dAssociations P < 0.05 are bolded and italicized